No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.6, pp.639-643, 2014 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 6
  • Publication Date: 2014
  • Doi Number: 10.5152/tjg.2014.6568
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.639-643
  • Keywords: Crohn's disease, ulcerative colitis, cannabinoid receptor-2, polymorphism, CB2 RECEPTOR, ULCERATIVE-COLITIS, CROHNS-DISEASE, PATHOGENESIS, RISK, EPIDEMIOLOGY, POLYMORPHISM, GENETICS, COLON, MICE

Abstract

Background/Aims: The endocannabinoid system can exert beneficial effects on gastrointestinal inflammation, and cannabinoid receptor-2 (CB2) agonists may represent a new therapeutic approach in inflammatory bowel disease (IBD). A functional CB2 Q63R polymorphism (rs35761398) in the CNR2 gene has been shown to affect the immunomodulating properties of the CB2 receptor. We sought to investigate whether the functional CB2 Q63R polymorphism (rs35761398) is associated with IBD susceptibility in a Turkish clinical sample.